Back to search results

MeMed BV® Test for Respiratory Infections

This study is testing a new diagnostic blood test called MeMed BV® for adults with respiratory tract infections (RTIs). The test aims to quickly tell if your infection is caused by bacteria or a virus. This could help doctors decide on the best treatment sooner. The study will compare patients who receive this new test along with usual care to those who only receive usual care. Researchers want to see if using the MeMed BV® test can reduce costs related to other diagnostic tests, specialist visits, and antibiotic use. You might be eligible if you are an adult with an RTI, have had a fever recently, and your symptoms started within the last 7 days. The study is currently unclear on its recruitment status and plans to enroll 100 participants.

Study design
This interventional study plans to enroll 100 adult participants. It compares a new diagnostic test with usual care to see how it affects patient management.
What's involved
You would have a blood sample taken for the MeMed BV® test in addition to standard blood draws. The study will track your care from admission to the emergency department up to about 28 days.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for about 28 days after admission to the emergency department to track costs and outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06070688

An Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED.

Recruiting
NAAges 18+InterventionalDiagnostic
The University of Texas Health Science Center, Houston
~100 participants
Updated 2026-01-23 on ClinicalTrials.gov
What's tested:MeMed BV® biomarker testUsual care

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cost of any additional diagnostic tests done by a participant
Measured over from day of admission to emergency department upto about 28 day follow up
+5 more outcomes measured

Conditions

Respiratory Tract Infections

Explore related trials

Respiratory tract infection

NCT06070688

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The University of Texas Health Science Center at Houston

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • David Robinson, MD,MS,MMM · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center, Houston

Who to contact

David Robinson, MD,MS,MMM
[email protected]
(713) 500-7873
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Current disease duration ≤ 7 days
Temperature ≥ 37.8°C (100°F) or tactile fever, noted at least once within the last 7 days
Clinical suspicion of bacterial or viral respiratory tract infection (RTI)
Written informed consent must be obtained from the patient or his/her legal guardian
Current disease duration ≤ 7 days
Clinical suspicion of bacterial or viral sepsis based on 2 or more SIRS criteria OR Clinical suspicion of bacterial or viral respiratory tract infection (RTI) AND temperature ≥ 37.8°C (100°F) or tactile fever, noted at least once within the last 7 days

Exclusion

Systemic antibiotics taken up to 48 hours prior to presentation
Outpatient steroids taken within 48 hours prior to presentation
Suspicion and/or confirmed diagnosis of infectious gastroenteritis/colitis
Inflammatory disease
Congenital immune deficiency (CID)
A proven or suspected infection on the presentation with Mycobacterial, parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen
Human immunodeficiency virus(HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (self-declared or known from medical records)
Major trauma and/or burns in the last 7 days
Major surgery in the last 7 days
Pregnancy - Self reported or medically confirmed
Active malignancy - Cancer diagnosed within the previous six months, recurrent, regionally advanced, or metastatic cancer, cancer for which treatment had been administered within six months, or hematological cancer that is not in complete remission.
Current treatment with immune-suppressive or immune-modulating therapies, at some point in the past 10 days
Hemodynamically unstable (require life-saving interventions such as vasopressors)
Patients transferred from another facility who already have a differentiated respiratory illness (known diagnosis e.g., culture positive results)
Consider unsuitable for the study by the study team
Systemic antibiotics taken up to 48 hours prior to presentation
Outpatient steroids taken within 48 hours prior to presentation
Suspicion and/or confirmed diagnosis of infectious gastroenteritis/colitis
Inflammatory disease (e.g., IBD, SLE, RA, other vasculitis)
Congenital immune deficiency (CID)
A proven or suspected infection on the presentation with Mycobacterial (e.g., MAC, MABC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen
HIV, HBV, or HCV infection (self-declared or known from medical records)
Major trauma and/or burns in the last 7 days
Major surgery in the last 7 days
Pregnancy - Self reported or medically confirmed
Active malignancy of a solid tumor - Cancer diagnosed within the previous six months, recurrent, regionally advanced, or metastatic cancer, cancer for which treatment had been administered within six months, or hematological cancer that is not in complete remission
Current treatment with immune-suppressive or immune-modulating therapies, at some point in the past 10 days
Hemodynamically unstable (require life-saving interventions such as vasopressors)
Patients transferred from another facility who already have a differentiated respiratory illness (known diagnosis e.g., culture positive results)

What this trial measures

  • Cost of any additional diagnostic tests done by a participantfrom day of admission to emergency department upto about 28 day follow up

    Additional diagnostic tests may include serial complete blood count (CBC)s, additional blood cultures, viral cultures and serial basic metabolic panel (BMP) blood bank

  • Cost of any additional consults done by a participantfrom day of day of admission to emergency department upto about 28 day follow up

    Comparative metric between the experimental and control groups

  • Total cost of any antimicrobial treatments by a participantend of study (about 28 days from baseline)

    Comparative metric between the experimental and control groups

  • Number of participants that were admitted to the hospitalend of study (about 28 days from baseline)

    Comparative metric between the experimental and control groups

  • Cost of hospital stayend of study (about 28 days from baseline)

    Total costs defined as all costs including lab and diagnostic services, blood bank, pharmaceuticals, nursing, consultants, and all other services listed in the patient's work-up. Comparative metric between the experimental and control groups

  • Length of hospital stayat time of discharge( from 28 days- 6months from baseline)

    Comparative metric between the experimental and control groups